PATENT CLAIM ANALYSIS

Application Number: 16097954
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["435", "006110"]

Abstract:
The present invention addresses the problem of how to provide a predictive marker useful for carcinogenesis surveillance after hepatitis C virus eradication. Provided is a predictive marker composed of a single nucleotide polymorphism specified by rs17047200. In the present invention, the single nucleotide polymorphism is detected in nucleic acid samples collected from subjects, thereby to examine the risk of developing hepatocellular carcinoma after of hepatitis C virus eradication.

Claim (Index 2):
The risk examination method according to  claim 1 , characterized by assessing the risk according to any of the following criteria:\n (a) the subject is at high risk if an allele with T as the single nucleotide polymorphic base is detected; (b) the risk is in the following order: risk in the case of type AA<risk in the case of type AT, risk in the case of type TT; and (c) the risk is in the following order: risk in the case of type AA<risk in the case of type AT<risk in the case of type TT.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.52083
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13982039', '14236869', '12594010', '14002642', '16133322']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6304813502963559
- 35 USC 102 Novelty (BERT): 0.5217609655988668
- Combined Prediction Score: 0.619609311826607
- Mean Citation Score: 283.005542
- Max Citation Score: 305.57544
- Similarity Product: 174.91609122343542

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test